Diaceutics (DXRX) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Jul 2024 07:00 AM
RNS
Senior Management Appointments
01 Jul 2024 07:00 AM
RNS
PDMR Shareholding/SIP and Total Voting Rights
24 Jun 2024 01:15 PM
RNS
Result of AGM
13 Jun 2024 07:00 AM
RNS
"Precision Medicine in Oncology " Virtual Event
06 Jun 2024 07:00 AM
RNS
Diaceutics - Capital Markets Event
29 May 2024 08:00 AM
RNS
Notice of AGM and Posting of Annual Report
29 May 2024 08:00 AM
RNS
Notice of AGM and Posting of Annual Report
28 May 2024 07:00 AM
RNS
Data to be Presented at 2024 ASCO Annual Meeting
24 May 2024 03:01 PM
RNS
PDMR Shareholding/SIP and Total Voting Rights
23 May 2024 07:00 AM
RNS
Director / PDMR Shareholding
21 May 2024 07:00 AM
RNS
Revenue growth of 22% & order book growth of 57%
16 May 2024 07:00 AM
RNS
Two New Enterprise-Wide Engagements
14 May 2024 07:00 AM
RNS
Diaceutics - Capital Markets Event
01 May 2024 07:00 AM
RNS
Notice of Results & Presentations
30 Apr 2024 07:00 AM
RNS
PDMR Shareholding/SIP and TVR
09 Apr 2024 07:00 AM
RNS
Appointment of Amie Mc Neice as VP of Marketing
05 Apr 2024 01:40 PM
RNS
Block Listing Return
03 Apr 2024 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
02 Apr 2024 07:00 AM
RNS
Director/PDMR/PCA Shareholding & TR1
21 Mar 2024 07:00 AM
RNS
Significant upgrade to Diaceutics' DXRX platform
19 Mar 2024 07:00 AM
RNS
Diaceutics forms landmark industry Forum
07 Mar 2024 07:00 AM
RNS
Director/PDMR Shareholding
01 Mar 2024 09:00 AM
RNS
PDMR Shareholding / SIP and TVR
27 Feb 2024 07:00 AM
RNS
Expanded lab network and data capabilities
14 Feb 2024 01:00 PM
RNS
Diaceutics PLC - Strategic alliance with KPMG
05 Feb 2024 07:00 AM
RNS
Appointment of VP, Scientific & Medical Services
01 Feb 2024 12:31 PM
RNS
PDMR Shareholding/Share Incentive Plan and TVR
30 Jan 2024 07:00 AM
RNS
Diaceutics PLC – Trading Update
25 Jan 2024 01:16 PM
RNS
Exercise of Warrant & Total Voting Rights
19 Jan 2024 07:00 AM
RNS
Diaceutics PLC – Financial Calendar Update
29 Dec 2023 01:18 PM
RNS
PDMR Shareholding/Share Incentive Plan
30 Nov 2023 12:59 PM
RNS
PDMR Shareholding/Share Incentive Plan and TVR
30 Nov 2023 07:00 AM
RNS
Diaceutics to attend Stifel Conference in NYC
21 Nov 2023 11:13 AM
RNS
Notification of Major Holdings
31 Oct 2023 12:38 PM
RNS
PDMR Shareholding/SIP & Total Voting Rights
11 Oct 2023 01:47 PM
RNS
PDMR Shareholding/Share Incentive Plan and TVR
02 Oct 2023 03:59 PM
RNS
Block Listing Application to AIM
29 Sep 2023 11:19 AM
RNS
Holding(s) in Company
29 Sep 2023 11:19 AM
RNS
Holding(s) in Company
26 Sep 2023 07:00 AM
RNS
Diaceutics PLC – Half Year Results
26 Sep 2023 07:00 AM
RNS
Diaceutics PLC - Planned CEO Transition
21 Sep 2023 02:37 PM
RNS
Diaceutics PLC – Directorate Changes
07 Sep 2023 07:00 AM
RNS
Attending 10th Annual HealthTech Investment Forum
05 Sep 2023 07:00 AM
RNS
Notice of Interim Results and Presentations
30 Aug 2023 02:56 PM
RNS
PDMR Shareholding/Share Incentive Plan
29 Aug 2023 07:00 AM
RNS
Diaceutics launches daily alerts for DXRX platform
04 Aug 2023 07:00 AM
RNS
Canaccord Genuity 43rd Annual Growth Conference
31 Jul 2023 03:19 PM
RNS
PDMR Shareholding/Share Incentive Plan
25 Jul 2023 07:00 AM
RNS
Trading Update and Notice of Results
29 Jun 2023 12:07 PM
RNS
PDMR Shareholding/Share Incentive Plan

Diaceutics PLC, a global leader in the field of precision medicine, holds a significant position on the London Stock Exchange (LSE). As part of the dynamic financial ecosystem facilitated by the London Stock Exchange Group (LSEG), Diaceutics PLC contributes to the global financial landscape.

The Diaceutics share price and DXRX share price are key indicators of the company's market performance. These metrics are closely monitored by investors to assess the company's financial health and make informed investment decisions.

Founded in 2005, Diaceutics PLC is headquartered in Belfast, United Kingdom. The company has been a pioneer in the field of diagnostic testing, collating large amounts of laboratory, patient, claims, and payor data which it uses to deliver diagnostic testing strategies to its clients. Over the years, Diaceutics PLC has amassed a set of data from over 52,515 laboratories, showing disease volumes and 481 million de-identified patient records globally in 53 countries. This data collection has allowed the company to accumulate a proprietary database of laboratory capabilities across the industry.

Diaceutics PLC provides services to 39 global pharmaceutical companies and is focused on optimising its clients’ strategies for the development and launch of precision medicines. Precision medicines are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis.

Being listed on the LSE, Diaceutics PLC is part of the vibrant financial ecosystem facilitated by the London Stock Exchange Group (LSEG). LSEG, a leading global financial markets infrastructure and data provider, plays a crucial role in supporting the financial stability and growth of communities and economies globally.

In conclusion, Diaceutics PLC, with its strategic focus on precision medicine and its status as a company listed on the LSE, represents a noteworthy entity in the financial markets landscape facilitated by LSEG. Its share price, referred to as both Diaceutics share price and DXRX share price, are key considerations for investors, reflecting the company's market performance. As part of the vibrant LSEG ecosystem, Diaceutics PLC contributes to the broader financial markets infrastructure, underscoring its significance in the global financial community.

UK 100

Latest directors dealings